Operating Segments (Tables)

9 Months Ended

Sep. 30, 2014

Operating Segments [Abstract]

Summary of segmental information

	Three Months Ended September 30,
	2014			2013
Contract/Grant Revenue
Vaccines/BioDefense	$	2,729,854		$	264,920
BioTherapeutics		57,855			47,571
Total	$	2,787,709		$	312,491
Income (Loss) from Operations
Vaccines/BioDefense	$	545,728		$	(419,929	)
BioTherapeutics		(4,855,765	)		(1,080,436	)
Corporate		(831,341	)		(360,297	)
Total	$	(5,141,378	)	$	(1,860,662	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	9,922		$	28,316
BioTherapeutics		49,985			29,233
Corporate		1,561			551
Total	$	61,468		$	58,100
Other Income /(Expense), Net
Corporate	$	791,823		$	(4,699,194	)
Stock-Based Compensation
Vaccines/BioDefense	$	17,224		$	39,493
BioTherapeutics		33,118			158,142
Corporate		110,653			209,256
Total	$	160,995		$	406,891

	Nine Months Ended  September 30,
	2014			2013
Revenues, Principally from Grants
Vaccines/BioDefense	$	4,928,284		$	1,683,265
BioTherapeutics		188,270			161,858
Total	$	5,116,554		$	1,845,123
Income (Loss) from Operations
Vaccines/BioDefense	$	949,032		$	(1,983,396	)
BioTherapeutics		(6,541,832	)		(2,068,703	)
Corporate		(2,834,318	)		(1,652,344	)
Total	$	(8,427,118	)	$	(5,704,443	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	29,666		$	83,951
BioTherapeutics		148,995			86,303
Corporate		5,299			1,412
Total	$	183,960		$	171,666
Other Income /(Expense), Net
Corporate	$	(202,662	)	$	(5,347,984	)
Stock-Based Compensation
Vaccines/BioDefense	$	38,124		$	61,742
BioTherapeutics		142,374			205,083
Corporate		278,416			304,346
Total	$	458,914		$	571,171

	As of  September 30,  2014		As of  December 31,  2013
Identifiable Assets
Vaccines/BioDefense	$	1,566,050	$	1,870,414
BioTherapeutics		265,939		386,721
Corporate		4,440,953		6,008,320
Total	$	6,272,942	$	8,265,455